Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This retrospective cohort study collected data of patients with huge hepatocellular carcinoma (HCC) treated between June 1, 2018, and December 31, 2023, through the hospital information system. Patients were divided into a neoadjuvant conversion-first cohort and an upfront surgery cohort based on whether they received preoperative locoregional therapy combined with targeted and immunotherapy. The conversion-first cohort was further stratified into a conversion surgery group and a non-surgery group according to whether curative-intent hepatectomy was ultimately achieved. The upfront surgery cohort was divided into a postoperative adjuvant therapy group and a postoperative surveillance group based on whether adjuvant immunotherapy was administered after surgery. The primary objective was to analyze differences in overall survival (OS) and progression-free survival (PFS) among the four groups and to evaluate the impact of neoadjuvant conversion therapy on the safety of hepatectomy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| upfront surgery with active surveillance |
| ||
| surgery with adjuvant treatment |
| ||
| neoadjuvant conversion surgery group |
| ||
| non-surgery |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| hepatectomy without immune checkpoint inhibitors-based adjuvant therapy | Procedure | All procedures were performed by senior hepato-pancreato-biliary surgeons who completed over 100 hepatectomy procedures annually. Intraoperative ultrasound was routinely performed to identify any potential tumor nodules that were not detected before surgery and to help rule out parenchymal transection plane. The resection margin should extend 1 cm beyond the tumor edge whenever possible. Pringle's maneuver and the low central venous pressure technique were performed routinely.For difficult hepatectomy, the anterior approach (parenchymal transection without prior mobilization of the liver) was applied and the hepatic pedicle and the inferior vena cava below the liver were clamped simultaneously for better hepatic vascular inflow and outflow control. Liver parenchymal transection was performed by an ultrasonic scalpel. After surgery, all patients were followed up according to the visit schedules and contents recommended by the Chinese guidelines for HCC. |
| Measure | Description | Time Frame |
|---|---|---|
| overall survival | From date of treatment until the date of death from any cause, assessed up to 66 months |
| Measure | Description | Time Frame |
|---|---|---|
| Progression-free survival | from the date of the first treatment to the date of tumor progression, assessed up to 66 months | |
| Textbook Outcome in Liver Surgery | A comprehensive indicator takes into account intraoperative incidents, postoperative bile leakage, postoperative liver failure, postoperative complications, R0 resection, readmission, and mortality |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients who were identified as potentially convertible huge HCC and underwent treatment between June 2018 and December 2023
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei | 430030 | China |
Not provided
Not provided
Not provided
Not provided
|
| hepatectomy with immune checkpoint inhibitors-based adjuvant therapy | Procedure | After surgery, patients who agreed to receive postoperative adjuvant therapy began to undergo immunotherapy when recovered well from the surgery and alanine aminotransferase and aspartate aminotransferase were both less than 80 U/L and total bilirubin was less than 2 mg/dL. Immune checkpoint inhibitors (ICIs) included pembrolizumab, atezolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab. The specific agents of ICIs were determined by the patients' wishes and consultation with their attending physicians. ICIs were injection once every 3 weeks for 12 months and would be terminated when disease progressed or intolerable toxicity occurred. Meanwhile, some patients underwent adjuvant transarterial chemoembolization (TACE) and/or target therapy. |
|
| neoadjuvant conversion therapy followed by surgery | Procedure | Patients were treated preoperatively with a combination of immune checkpoint inhibitors (ICIs), targeted drugs, and locoregional interventions, such as transarterial chemoembolization (TACE) and/or and/or hepatic artery infusion chemotherapy (HAIC).ICIs included pembrolizumab, atezolizumab, tislelizumab, sintilimab, camrelizumab, toripalimab, and durvalumab. Targeted drugs included lenvatinib, bevacizumab, donafenib, sorafenib, regorafenib, and apatinib. The choice of different locoregional therapies and systemic therapy agents for HCC was made by weighing the patient's wishes, cost considerations, and multidisciplinary team (MDT) discussions. ICIs and targeted drugs were used until the disease progressed or an intolerable adverse event occurred. |
|
| Non-surgery | Drug | Patients who received the neoadjuvant conversion therapy but eventually not underwent surgery |
|
| Within 90 days following surgery |
| ID | Term |
|---|---|
| D006498 | Hepatectomy |
| ID | Term |
|---|---|
| D013505 | Digestive System Surgical Procedures |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided